ReviewEffect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know?
Section snippets
Conflict of interest
Y.L. has received speaker fees, research or travel grants from Servier (manufacturer of ivabradine). C.V. was an investigator in a clinical trial sponsored by Servier investigating the effect of ivabradine on central blood pressure, but did not receive any personal fees for this activity.
Ethics
The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology.
Informed consent was obtained from each patient and the study protocols conform to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by institution's human research committees.
Acknowledgments
We thank Julie Salzmann, PhD, who provided the medical writing assistance on behalf of Servier, France.
References (11)
- et al.
Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (conduit artery function evaluation) study: CAFE-heart rate
J. Am. Coll. Cardiol.
(2009) - et al.
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension
J. Am. Coll. Cardiol.
(2008) - et al.
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study
Circulation
(2006) - et al.
Beta-blockers for hypertension
Cochrane Database Syst. Rev.
(2012) - et al.
Impact of ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease
Hypertension
(2015)